FDA Brief

Warning letters Drugs

FDA warning letter to

Eksa Mills S.A. de C.V.

High riskIssued Oct 5, 2022Posted Oct 11, 2022Center for Drug Evaluation and Research | CDER

FDA cited Eksa Mills for CGMP violations, including shared-equipment contamination risks, after an April 2022 inspection of its Mexican drug facility.

What happened

FDA inspected Eksa Mills' drug manufacturing facility in Heroica Puebla De Zaragoza, Puebla, Mexico, from April 18 to April 19, 2022. Investigators found the company made OTC drugs on the same equipment used for commercial chemical solutions without adequate cleaning procedures or equipment use logs, and found the quality unit failed to provide adequate oversight. FDA said the company's April 24, 2022 response to its Form FDA 483 inspection observations was inadequate.

What FDA found

  1. The company did not clean and maintain drug manufacturing equipment at appropriate intervals to prevent contamination.

    21 CFR 211.67(a)
  2. The company made OTC drugs on the same equipment used for commercial chemical solutions and lacked written cleaning procedures and equipment use logs for the tanks.

    21 CFR 211.67(a)
  3. The quality unit — the group responsible for quality oversight — lacked adequate written procedures for its roles, vendor qualification, batch release, reserve samples, investigations, complaints, and CGMP training.

    21 CFR 211.22(a) and (d)
  4. The company did not adequately test incoming components for identity, purity, strength, and other quality attributes.

    21 CFR 211.84(d)(1) and (2)
  5. The company did not follow an adequate stability program.

    21 CFR 211.166(a)
  6. The company did not adequately maintain batch records.

    21 CFR 211.188

What FDA wants

FDA tells the company to respond in writing within 15 working days with what it has done to correct the violations and prevent recurrence. It also asks the company to stop making drugs on equipment shared with non-pharmaceuticals and, if it plans to resume, to provide a separation plan, a risk assessment for previously made drugs, quality unit remediation, and notification before resuming.

Who should pay attention

  • companies that buy OTC drug products from this manufacturer
  • distributors of its drug products
  • firms that rely on shared drug and industrial-chemical equipment

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk